Nxera Pharma Co., Ltd.
Notification of Submission of Marketing Authorization Application in South Korea for Duchenne Muscular Dystrophy Treatment Vamorolone
Announced submission of a marketing authorization application for vamorolone in South Korea. ODD and GIFT designations already obtained. Targeting approval in 2027 and commercial launch in 2028. Positioning South Korea expansion as a mid-to-long-term growth strategy; no impact on full-year results for the fiscal year ending December 2026.
Key Figures
- Marketing authorization application: Marketing authorization application in South Korea (MFDS)
- ODD and GIFT designations: ODD and GIFT designations obtained
- Target launch timing: 2028
AI要約
Summary of the News
Nxera Pharma Co., Ltd. announced that it has submitted a marketing authorization application for vamorolone, a treatment for Duchenne muscular dystrophy (DMD), to the MFDS in South Korea. Orphan Drug Designation (ODD) and GIFT designation have already been obtained, and the company aims to secure approval in 2027 and achieve commercial launch in 2028.
Outlook in South Korea and Long-Term Strategy
The South Korea rollout of vamorolone is an important milestone to provide new treatment options for DMD patients. Leveraging approval experience in the United States, EU, United Kingdom, and China, the company will lead activities to obtain local approval. In the long term, the initiative is expected to improve business revenue and corporate value.
Nxera Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
